What place does naltrexone have in the treatment of alcoholism?

CNS Drugs

Volumn 18, Issue 9, 2004, Pages 547-560

  Rohsenow, Damaris J ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NALTREXOL; NALTREXONE; NEUROLEPTIC AGENT;

ALCOHOLISM; CLINICAL TRIAL; COGNITION; COMPLIANCE (PHYSICAL); COUNSELING; DRINKING; FATIGUE; HUMAN; NAUSEA; PRIORITY JOURNAL; RELATIVE; REVIEW; WITHDRAWAL SYNDROME;

ALCOHOLISM; CLINICAL TRIALS; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 3242667730     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418090-00001     Document Type: Review

References (40)

1. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881-7
2. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80
3. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734-9
4. O'Malley SS, Croop RS, Wroblewski JM, et al. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr Ann 1995; 25: 681-8
5. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53: 217-24
6. Anton RF, Moak DH, Waid R, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156: 1758-64
7. Heinala P, Alho H, Kilanmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21: 287-92
8. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 1998; 22: 1074-9
9. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10: 258-68
10. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and one-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634-47
11. Morris PLP, Hopwood M, Whelan G, et al. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96: 1565-73
12. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996; 13: 35-9
13. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54: 737-42
14. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: Results from a multicenter clinical trial. Alcohol Clin Exp Res 2002; 26: 1381-7
15. Chick J, Anton R, Checinski K, et al. A multisite, randomized, double-blind placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35: 587-93
16. Balldin J, Berglund M, Bong S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003; 27: 1142-9
17. Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002; 176: 530-4
18. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56: 719-24
19. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology 1992; 6: 39-48
20. Gatspar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharm 2002; 22: 592-8
21. Feinstein AR. Current problems and future challenges in randomized clinical trials. Circulation 1984; 70: 767-74
22. Peto R, Pike M, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. analysis and examples. Br J Cancer 1977; 35: 1-39
23. Davidson D, Palfai T, Bird C, et al. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 1999; 23: 195-203
24. Swift RM, Whelihan W, Kuznetsov O, et al. Naltrexone-induced alternations in human ethanol intoxication. Am J Psychiatry 1994; 151: 1463-7
25. Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol "high" in humans. Am J Psychiatry 1995; 152: 613-5
26. Schmitz JM, Stotts AL, Rhoades HM, et al. Naltrexone and relapse prevention treatment for cocaine dependent patients. Addict Behav 2001; 26: 167-80
27. Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000; 24: 1542-9
28. Rohsenow DJ, Monti PM, Rubonis AV, et al. Cue exposure with coping skills training and communication skills training for alcohol dependence: six and twelve month outcomes. Addiction 2001; 96: 1161-74
29. Onken LS, Blaine JD, Boren JJ. Integrating behavioral therapies with medications in the treatment of drug dependence. Research Monograph 150, National Institute on Drug Abuse, US Government Printing Office, 1995
30. Monti PM, Rohsenow DJ, Hutchison K, et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999; 23: 1386-94
31. Rohsenow DJ, Monti PM, Hutchison KE, et al. Naltrexone's effects on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol 2000; 109: 738-42
32. Rohsenow DJ, Monti PM, Abrams DB, et al. Cue elicited urge to drink and salivation in alcoholics: relationship to individual differences. Adv Behav Res Ther 1992; 14: 195-210
33. Davidson D, Swift RM, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 1996; 20: 732-9
34. King AC, Volpicelli JR, Frazer A, et al. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 1997; 129: 15-22
35. McCaul ME, Wand GS, Sullivan J, et al. Beta-naltrexol level predicts alcohol relapse [abstract]. Alcohol Clin Exp Res 1997; 21: 32A
36. The COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res 2003; 27: 1107-22
37. The COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcohol Clin Exp Res 2003; 27: 1123-31
38. Jaffe AJ, Rounsaville B, Chang G, et al. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64: 1044-53
39. Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003; 28: 1882-8
40. Hutchison KE, McGeary J, Smolen A, et al. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 2002; 2: 139-46